The Direct Cost Burden of Illness (BOI) of Lennox-Gastaut Syndrome (LGS) in the US (P6.272)

Objective: Determine the direct cost burden of LGS. Background: The economic burden of LGS, a severe childhood-onset epilepsy, has not been well studied. Design/Methods Commercial and Medicaid insurance-claim records (2010–2015) were queried to identify patients with intractable epilepsy, intellectual disability, and ≥1 antiepileptic drug (AED) prescription, with ≥2 years data. After excluding patients with conditions that preclude LGS (e.g., probable Dravet syndrome), rufinamide, used predominately for LGS, was selected as a key indicator. Characteristics significantly predictive of rufinamide use vs. a non-LGS condition were evaluated in non–rufinamide users meeting all other inclusion criteria. Controls were matched to patients with LGS by age, gender, US region, and consistent insurance coverage. Direct medical costs and utilization were assessed for 2 years from date of first epilepsy/seizure diagnosis or AED. Costs (normalized to 2017 dollars at 3%/annum) and utilization were averaged and reported on a per-patient-per-year (PPPY) basis. Results: Of 6019 patients with probable LGS identified, 2270 had Commercial insurance and 3749 had Medicaid. Mean age was 13 years (53% male). LGS patients utilized medical services >8 times the frequency of controls (p Conclusions: Direct costs associated with LGS are substantial, highlighting the need for new LGS treatments. Study Supported by: Greenwich Biosciences Disclosure: Dr. Story has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Greenwich Biosciences. Dr. Story holds stock and/or stock options in Greenwich Biosciences. Dr. Montouris has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EISAI,LUNDBECK, SK LIFE, UCB PHARMA FOR EXPERT PANEL ON PREGNANCY ,ACCORDA THERAPEUTICS. Dr. Funk has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Strategic Health Resources, Greenwich Biosciences, Relypsa, Jazz Pharmaceuticals, Tricida, Target PharmaSolutions, OptiScan. Dr. Saurer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Greenwich Biosciences. Dr. Saurer holds stock and/or stock options in Greenwich Biosciences. Dr. Reaven has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Strategic Health Resources. Dr. Reaven has received research support from Strategic Health Resources.